Rutherford, August 21, 2012 — Cancer Genetics, Inc. (CGI), a leader in oncology-focused personalized medicine, today announced that Inc. magazine ranked the company #232 among private Healthcare companies, and #2859 overall on its sixth annual Inc. 500|5000 list, an exclusive ranking of the nation’s fastest-growing private companies. The list represents a comprehensive look at the most important segment of the economy—America’s independent entrepreneurs. This was the first year the Company has been on the list, and is among the first oncology-focused molecular diagnostic companies on the list.
Panna Sharma, CEO of Cancer Genetics, Inc. says “Our team takes tremendous pride in being among other great companies and in our ability to scale our unique focus on personalizing the diagnosis for cancer patients. This recognition by Inc. results from the dedication of CGI’s employees and our commitment towards paving the way of personalized medicine in oncology.”
In a stagnant economic environment, median growth rate of 2012 Inc. 500|5000 companies remains an impressive 97 percent. The companies on this year’s list report having created over 400,000 jobs in the past three years, and aggregate revenue among the honorees reached $299 billion.
Complete results of the Inc. 5000, including company profiles, methodology and an interactive database that can be sorted by industry, region, and other criteria, can be found at www.inc.com/5000.
“Now, more than ever, we depend on Inc. 500/5000 companies to spur innovation, provide jobs, and drive the economy forward. Growth companies, not large corporations, are where the action is,” says Inc. Editor Eric Schurenberg.
About Cancer Genetics, Inc.
Cancer Genetics, Inc. (CGI) is an emerging leader in the field of personalized medicine, offering products and services that enable cancer diagnostics as well as treatments that are tailored to the specific genetic profile of the individual. CGI is committed to maintaining the standard of clinical excellence through its investment in outstanding facilities and equipment. Our reference laboratory is both CLIA certified and CAP accredited. In addition we have approvals and accreditations from the states of Florida, Maryland, New York, and New Jersey. The company has been built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, as well as strong research collaborations with major cancer centers such as Memorial Sloan-Kettering and the National Cancer Institute.
For further information, www.cancergenetics.com.